Dr. Xiaojing Zhang 张晓晶
Chief Physician
Department of Bone and Soft Tissue Tumors, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of bone and soft tissue tumors, including limb perfusion chemotherapy, joint reconstruction for malignant tumors, melanoma research and therapy, metastatic tumor management, and limb-sparing surgery.
Dr. Zhang is Chief Physician and Department Head at Liaoning Cancer Hospital & Institute, with over 20 years of experience. A postdoctoral fellow at the University of Alberta Cancer Research Institute, Dr. Zhang serves as a master’s supervisor and receives a special government allowance. Research collaborations include the University of Alberta and China Medical University. Awards include Second and Third Prizes for Liaoning Provincial Scientific and Technological Progress.
Professional roles
- Standing Committee Member, Sarcoma Committee, China Anti-Cancer Association
- Deputy Leader, Melanoma Group, China Anti-Cancer Association
- Chair, Sarcoma Committee, Liaoning Anti-Cancer Association
- Member, Multinational Association of Supportive Care in Cancer (MASCC)
Name order: in Chinese the family name comes first (Zhang Xiaojing). Papers usually list the name as Xiaojing Zhang or Zhang X.
Selected publications
27 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Cancer, 2021 (senior author): CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis. PubMed 34876132
- Front Oncol, 2021 (senior author): Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience. PubMed 34367981
- Neoplasma, 2021 (senior author): Establishment and validation of prognostic nomograms to predict overall survival and cancer-specific survival for patients with osteosarcoma. PubMed 33118831
- Life Sci, 2020 (senior author): Magnoflorine inhibits the malignant phenotypes and increases cisplatin sensitivity of osteosarcoma cells via regulating miR-410-3p/HMGB1/NF-κB pathway. PubMed 32553931
- Cancer Manag Res, 2020 (senior author): CONUT Score or/and Peripheral Blood CD4+/CD8+ Ratio-Based Web Dynamic Nomograms to Predict the Individualized Survival of Patients with Advanced Osteosarcoma. PubMed 32581591
- BMC Cancer, 2020 (senior author): Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis. PubMed 32228518
- J Cell Mol Med, 2020 (senior author): Extracellular nanovesicles-transmitted circular RNA has_circ_0000190 suppresses osteosarcoma progression. PubMed 31923350
- World J Surg Oncol, 2020 (senior author): Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma. PubMed 32000789
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion